Harmonizing the Regulatory Framework
After MJBizDaily was the first news outlet to report about the World Health Organization’s recommendations to reschedule cannabis, a wave or articles, reports and enthusiasm shook the industry. But change at a multilateral UN level always takes longer than expected. In the following months, voting on the recommendations was postponed, the International Narcotics Control Board (INCB) heavily criticized Canada in its annual report and the EU issued a resolution calling for only cannabis that has undergone clinical trials to be available.
You’ll get insights on:
- The probability of meaningful change at a UN level and the implications it could have for member states.
- The INCB report that criticized “poorly regulated” medical cannabis frameworks in North America while tacitly accepting the more restrictive ones in Europe.
- The EU resolution that appears to benefit pharmaceutical products that have undergone clinical trials.
- Possible regulatory harmonization of CBD at an EU-level.